R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops in the U.S. Market

Published: Feb 21, 2013

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (hereinafter referred to as "Sucampo") announced that RESCULA® Eye Drops had been launched in the U.S. market. (See Sucampo's press release dated February 19, 2013.) RESCULA® Eye Drops may be used as a first-line agent or concomitantly with other topical ophthalmic drug products with ocular hypotensive effect for treatment of open-angle glaucoma, which is the most common form of glaucoma, or ocular hypertension. RESCULA® Eye Drops is a BK channel activator, which is different from other intraocular pressure-lowering agents. Contract for assignment of marketing approval and dealership of RESCULA® Eye Drops, licensing of related patents, and exclusive manufacturing and provision of the product in the U.S. and Canada for indications of glaucoma and ocular hypertension was made between Sucampo and us in April 2009.

Back to news